Revising the upper limit of normal for levels of serum alanine aminotransferase in a middle eastern population with normal liver histology

Digestive Diseases and Sciences

Volumn 58, Issue 8, 2013, Pages 2369-2375

  Al Hamoudi, Waleed ^a,b   Ali, Safiyya ^a   Hegab, Bassem ^b,c   Elsiesy, Hussien ^b   Hashim, Almoutaz ^b   Al Sofayan, Mohammed ^b   Khalaf, Hatem ^b   Al Bahili, Hamad ^b   Al Masri, Nasser ^b   Al Sebayel, Mohammed ^b   Broering, Dieter ^b   Abdo, Ayman ^a   Alqahtani, Saleh ^b   Abaalkhail, Faisal ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^c MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Alanine aminotransferase; Liver biopsy; Steatosis; Upper limit of normal

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIVER BIOPSY; LIVER HISTOLOGY; MALE; MIDDLE EAST; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ALANINE TRANSAMINASE; FEMALE; HUMANS; LIVER; MALE; SAUDI ARABIA; TISSUE DONORS; YOUNG ADULT;

EID: 84881477563     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2659-0     Document Type: Article

References (24)

1. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342:1266-1271.
2. Kaplan MM. Alanine aminotransferase levels. What's normal? Ann Intern Med. 2002;137:49-51.
3. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28:339-350.
4. Amarapurkar DN, Hashimoto E, Lesmana LA, et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol. 2007;22:788-793.
5. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1-10.
6. Sanai FM, Helmy A, Dale C, et al. Updated thresholds for alanine aminotransferase do not exclude significant histological disease in chronic hepatitis C. Liver Int. 2011;31:1039-1046.
7. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315-1341.
8. Lee JK, Shim JH, Lee HC, et al. Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology. 2010;51:1577-1583.
9. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol. 2006;101:76-82.
10. Kariv R, Leshno M, Beth-Or A, et al. Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver Int. 2006;26:445-450.
11. Mohamadnejad M, Pourshams A, Malekzadeh R, et al. Healthy ranges of serum alanine aminotransferase levels in Iranian blood donors. World J Gastroenterol. 2003;9:2322-2324.
12. Lozano M, Cid J, Bedini JL, Mazzara R, et al. Study of serum alanine-aminotransferase levels in blood donors in Spain. Haematologica. 1998;83:237-239.
13. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285.
14. Al-hamoudi W, El-Sabbah M, Ali S, et al. Epidemiological, clinical, and biochemical characteristics of Saudi patients with nonalcoholic fatty liver disease: a hospital-based study. Ann Saudi Med. 2012;32:288-292.
15. El-Hassan AY, Ibrahim EM, Al-Mulhim FA, Nabhan AA, Chammas MY. Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. Br J Radiol. 1992;65:774-778.
16. Fan JG, Saibara T, Chitturi S, et al. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol. 2007;22:794-800.
17. Kim HJ, Kim HJ, Lee KE, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med. 2004;164:2169-2175.
18. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307:491-497.
19. Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, et al. Diabetes mellitus in Saudi Arabia. Saudi Med J. 2004;25:1603-1610.
20. Al-Nozha MM, Al-Mazrou YY, Al-Maatouq MA, et al. Obesity in Saudi Arabia. Saudi Med J. 2005;26:824-829.
21. Piton A, Poynard T, Imbert-Bismut F, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology. 1998;27:1213-1219.
22. Ruhl CE, Everhart JE. Trunk fat is associated with increased serum levels of alanine aminotransferase in the United States. Gastroenterology. 2010;138:1346-1356, 1356.e1-1356.e3.
23. Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology. 2005;42:650-656.
24. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592-1609.